Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2018 Mar 9

PMID 29515406

Citations 2

Authors

Taku Fujimura

Kayo Tanita

Yota Sato

Yumi Kambayashi

Sadanori Furudate

Akira Tsukada

Akira Hashimoto

Setsuya Aiba

Affiliations

Soon will be listed here.

Abstract

Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

Citing Articles

Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.

Fujimura T, Amagai R, Kambayashi Y, Aiba S Pharmaceutics. 2021; 13(2).

PMID: 33540765 PMC: 7913115. DOI: 10.3390/pharmaceutics13020200.

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.

Tanita K, Fujimura T, Kambayashi Y, Tsukada A, Sato Y, Hashimoto A Case Rep Oncol. 2018; 11(1):114-118.

PMID: 29606949 PMC: 5869583. DOI: 10.1159/000487127.

References

Furudate S, Fujimura T, Kakizaki A, Hidaka T, Asano M, Aiba S . Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci. 2016; 83(3):182-9. DOI: 10.1016/j.jdermsci.2016.05.004. View

Furudate S, Fujimura T, Kakizaki A, Kambayashi Y, Asano M, Watabe A . The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides. Exp Dermatol. 2015; 25(2):107-12. DOI: 10.1111/exd.12873. View

Wu X, Schulte B, Zhou Y, Haribhai D, Mackinnon A, Plaza J . Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014; 134(11):2814-2822. DOI: 10.1038/jid.2014.206. View

Ni X, Jorgensen J, Goswami M, Challagundla P, Decker W, Kim Y . Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res. 2014; 21(2):274-85. DOI: 10.1158/1078-0432.CCR-14-0830. View

Duvic M, Pinter-Brown L, Foss F, Sokol L, Jorgensen J, Challagundla P . Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015; 125(12):1883-9. PMC: 4375715. DOI: 10.1182/blood-2014-09-600924. View